Gangliosidosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:309144
Who is this for?
Show terms as
3Active trials33Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Gangliosidosis is a group of rare inherited metabolic diseases that belong to a family of conditions called lysosomal storage disorders. In these diseases, the body lacks certain enzymes needed to break down fatty substances called gangliosides, which are found mainly in the brain and nervous system. When these fats build up in cells, they cause progressive damage, especially to the brain and nerves. There are two main types: GM1 gangliosidosis and GM2 gangliosidosis. GM1 gangliosidosis is caused by a deficiency of the enzyme beta-galactosidase, while GM2 gangliosidosis includes Tay-Sachs disease and Sandhoff disease, caused by deficiencies in hexosaminidase enzymes. Each type can range from severe infantile forms to milder late-onset forms. Symptoms typically include developmental regression, seizures, vision loss, muscle weakness, and intellectual disability. In the most severe forms, symptoms begin in infancy and progress rapidly. Currently, there is no cure for gangliosidosis. Treatment focuses on managing symptoms and improving quality of life. Research into gene therapy, enzyme replacement therapy, and substrate reduction therapy is ongoing and offers hope for future treatments.

Key symptoms:

Developmental regression or loss of previously learned skillsSeizuresVision loss or blindnessCherry-red spot on the back of the eyeMuscle weakness and poor muscle toneIntellectual disabilityDifficulty swallowingExaggerated startle response to loud noisesEnlarged liver and spleenSkeletal abnormalitiesCoarse facial featuresMovement problems and stiffnessFeeding difficultiesSpeech and language problemsProgressive loss of motor skills

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

4 events
Jun 2026A Phase I Study of Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Tippi Mackenzie — PHASE1

TrialNOT YET RECRUITING
Jun 2025A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Azafaros A.G. — PHASE3

TrialRECRUITING
Aug 2019A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

National Human Genome Research Institute (NHGRI) — PHASE1, PHASE2

TrialRECRUITING
Dec 2010A Natural History Study of the Gangliosidoses

University of Minnesota

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Gangliosidosis.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
Phase 3
Actively Recruiting
· Sites: Oakland, California; Minneapolis, Minnesota +34 more · Age: 499 yrs
Other1 trial
A Natural History Study of the Gangliosidoses
Actively Recruiting
PI: Jeanine R. Jarnes, PharmD (University of Minnesota - Fairview) · Sites: Minneapolis, Minnesota

Specialists

Showing 25 of 33View all specialists →
MA
Maria T Acosta
Specialist
3 Gangliosidosis publications
TF
Terence R Flotte
WORCESTER, MA
Specialist
3 Gangliosidosis publications
JJ
Jean M Johnston
Specialist
3 Gangliosidosis publications
AM
Anne S Maguire
Specialist
2 Gangliosidosis publications
MB
Meghan Blackwood
MIAMISBURG, OH
Specialist
3 Gangliosidosis publications
RK
Rauan Kaiyrzhanov
Specialist
2 Gangliosidosis publications
CT
Cynthia J Tifft
WASHINGTON, DC
Specialist
5 Gangliosidosis publications
DM
Douglas R Martin
Specialist
4 Gangliosidosis publications
CL
Connor J Lewis
Specialist
4 Gangliosidosis publications
XJ
Xuntian Jiang
Specialist
3 Gangliosidosis publications
ZV
Zeynep Vardar
FORT MYERS, FL
Specialist
3 Gangliosidosis publications
ER
Eva-Maria Ratai
Specialist
3 Gangliosidosis publications
AK
Allison M Keeler
WENATCHEE, WA
Specialist
3 Gangliosidosis publications
MS
Miguel Sena-Esteves
Specialist
3 Gangliosidosis publications
PM
Paul Orchard, MD
MINNEAPOLIS, MN
Specialist
PI on 15 active trials
FM
Florian Eichler, MD
BOSTON, MA
Specialist
PI on 4 active trials
AM
Adeline Vanderver, MD
Los Angeles, California
Specialist

Rare Disease Specialist

PI on 4 active trials1 Gangliosidosis publication
JP
Jeanine R. Jarnes, PharmD
MINNEAPOLIS, MN
Specialist
PI on 3 active trials
JM
Joe TR Clarke, MD
Specialist
PI on 1 active trial
JM
Joanne Kurtzberg, MD
DURHAM, NC
Specialist
PI on 11 active trials
JM
Joe T Clarke, MD
Specialist
PI on 1 active trial
CM
Cynthia J Tifft, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 2 active trials
AM
Anupam Sehgal, MBBS
Kingston, Ontario
Specialist

Rare Disease Specialist

PI on 1 active trial
TM
Terence Flotte, MD
WORCESTER, MA
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Gangliosidosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open GangliosidosisForum →

No community posts yet. Be the first to share your experience with Gangliosidosis.

Start the conversation →

Latest news about Gangliosidosis

Disease timeline:

New recruiting trial: A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

A new clinical trial is recruiting patients for Gangliosidosis

New recruiting trial: A Natural History Study of the Gangliosidoses

A new clinical trial is recruiting patients for Gangliosidosis

New recruiting trial: A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

A new clinical trial is recruiting patients for Gangliosidosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific type of gangliosidosis does my child have, and what does this mean for the expected disease course?,Are there any clinical trials or experimental treatments currently available that we should consider?,What therapies and supportive services should we start now to maximize quality of life?,Should other family members be tested as carriers, and what does this mean for future pregnancies?,When should we consider palliative care, and what does that involve?,What emergency signs should I watch for, and what is the plan if they occur?,Are there any dietary or nutritional interventions that could help?

Common questions about Gangliosidosis

What is Gangliosidosis?

Gangliosidosis is a group of rare inherited metabolic diseases that belong to a family of conditions called lysosomal storage disorders. In these diseases, the body lacks certain enzymes needed to break down fatty substances called gangliosides, which are found mainly in the brain and nervous system. When these fats build up in cells, they cause progressive damage, especially to the brain and nerves. There are two main types: GM1 gangliosidosis and GM2 gangliosidosis. GM1 gangliosidosis is caused by a deficiency of the enzyme beta-galactosidase, while GM2 gangliosidosis includes Tay-Sachs dis

How is Gangliosidosis inherited?

Gangliosidosis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Gangliosidosis?

Yes — 3 recruiting clinical trials are currently listed for Gangliosidosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Gangliosidosis?

25 specialists and care centers treating Gangliosidosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.